Results 211 to 220 of about 13,281 (220)
Some of the next articles are maybe not open access.Related searches:
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
New England Journal of Medicine, 2023 BACKGROUND
Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma.F. del Bufalo, B. De Angelis, Ignazio Caruana, G. Del Baldo, M. A. De Ioris, Annalisa Serra, A. Mastronuzzi, M. Cefalo, D. Pagliara, Matteo Amicucci, G. Li Pira, Giovanna Leone, V. Bertaina, M. Sinibaldi, S. Di Cecca, M. Guercio, Z. Abbaszadeh, Laura Iaffaldano, M. Gunetti, S. Iacovelli, Rossana Bugianesi, S. Macchia, M. Algeri, P. Merli, F. Galaverna, Rachid Abbas, M. Garganese, M. F. Villani, G. Colafati, F. Bonetti, M. Rabusin, K. Perruccio, Veronica Folsi, C. Quintarelli, F. Locatelli +34 moresemanticscholar +1 more sourceGD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial
Nature MedicineF. Locatelli, D. Pagliara, M. A. De Ioris, Marco Becilli, G. Del Baldo, A. Serra, A. Mastronuzzi, M. Cefalo, G. Li Pira, Giovanna Leone, V. Bertaina, F. Fabozzi, Matteo Di Nardo, Chiara Rosignoli, M. L. D'Andrea, A. Crocoli, Sabina Vennarini, M. Sinibaldi, S. Di Cecca, M. Guercio, Laura Iaffaldano, B. Lucarelli, M. Algeri, P. Merli, G. Colafati, B. De Angelis, C. Quintarelli, F. del Bufalo +27 moresemanticscholar +1 more sourceDonor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma
Nature MedicineC. Quintarelli, F. del Bufalo, M. A. De Ioris, M. Guercio, M. Algeri, D. Pagliara, Domenico A Silvestris, Matteo Di Nardo, M. Sinibaldi, S. Di Cecca, Laura Iaffaldano, Simona Manni, Valentina Fustaino, M. Garganese, G. Colafati, V. Bertaina, Marco Becilli, A. Mastronuzzi, F. Fabozzi, Monica Gunetti, S. Iacovelli, Rossana Bugianesi, Stefania Macchia, G. Li Pira, M. Cefalo, Giovanna Leone, G. Del Baldo, B. De Angelis, F. Locatelli +28 moresemanticscholar +1 more source